Preclinical comparison of [ 177 Lu]Lu-rhPSMA-10.1 and [ 177 Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies.

Alexander WurzerFrancesco De RoseSebastian FischerMarkus SchwaigerWolfgang WeberStephan NekollaHans-Jürgen WesterMatthias EiberCalogero D'Alessandria

Published in: EJNMMI radiopharmacy and chemistry (2024)

Lu]Lu-rhPSMA-10.1 is currently being investigated in clinical phase I/II studies in patients with mCRPC (NCT05413850), in patients with high-risk localized PC (NCT06066437, Nautilus Trial) and after external beam radiotherapy (NCT06105918).

Keyphrases

prostate cancer
clinical trial
radiation therapy
randomized controlled trial
radical prostatectomy
squamous cell carcinoma
stem cells
study protocol
mesenchymal stem cells
phase iii
cell therapy
high resolution
phase ii